Janssen Presents Updated Data on First-in-Class Talquetamab at ASCO Suggesting Deep and Durable Responses in Heavily Pretreated Patients with Multiple Myeloma streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
5/17/21
Nutley is one of the top - if not THE top - supporters for Relay for Life. As we come out of our Pandemic cocoons, why not join this might effort to help those with cancer?
The American Cancer Society (ACS) reports that 1.9 million new cancer cases will be diagnosed. And more than 600,000 people will die from cancer. But due to the Pandemic, with so many dying from COVID-19 and also a backlog of reporting of cancer cases and deaths, the ACS reports These numbers do not account for the effect the COVID-19 pandemic has likely had on cancer diagnoses and deaths because they are projections based on reported cases and deaths through 2017 and 2018, respectively. More details about COVID-19 and its impact on cancer is available in the
Share this article
Share this article
LONDON, April 22, 2021 /PRNewswire/ GlaxoSmithKline plc (LSE/NYSE: GSK) today announced that the US Food and Drug Administration (FDA) has approved JEMPERLI (dostarlimab-gxly), a programmed death receptor-1 (PD-1) blocking antibody, based on the company s Biologics License Application. JEMPERLI is indicated for the treatment of adult patients with mismatch repair-deficient (dMMR) recurrent or advanced endometrial cancer, as determined by an FDA-approved test, that have progressed on or following prior treatment with a platinum-containing regimen. This indication is approved under accelerated approval based on tumor response rate and durability of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s).
A unique signature set of genes involved in cell death could help distinguish between lung cancer patients who will die early and those who will survive longer, potentially pointing the way to better diagnose and treat patients, according to new research from Medical College of Georgia.
Lung cancer is the leading cause of cancer death in both men and women and will kill 131,880 people this year, including 4,200 in Georgia and 2,550 in South Carolina, according to the American Cancer Society s Cancer Facts & Figures 2021. While survival has increased in many cancers over the last several decades with improved diagnostics and therapies, the five-year survival rate for lung cancer remains around 21%, the cancer society showed.
Share this article
Share this article
SAN FRANCISCO, March 3, 2021 /PRNewswire/ Blue Note Therapeutics, Inc., today announced the closing of a Series A financing round of $26.25 million. Proceeds will allow the company to scale the organization and fund near-term clinical trials of its lead prescription digital therapeutic (PDT), which will potentially improve the treatment of cancer. The capital will also support the development of Blue Note s pipeline assets. The Series A financing was led by JAZZ Venture Partners and joined by Summer VC.
Blue Note Therapeutics is dedicated to serving patients suffering from cancer-related distress. Working closely with leading cancer research centers and patient communities, Blue Note is developing clinically validated medical devices designed to improve overall cancer outcomes. These products will help address the specific psychosocial needs of oncology patients and may reduce comorbidities such as anxiety, depression, and fear of cancer re